Tech Urol 2001 Mar;7(1):44-6
Division of Urology, Harbor-UCLA Medical Center, UCLA School of Medicine, Torrance, California, USA.
PURPOSE: Interstitial cystitis (IC) is a disorder of unknown etiology with few effective therapies. Oral bioflavonoid therapy utilizing quercetin recently proved to be clinically effective in men with chronic pelvic pain syndrome, a disorder with similarities to IC. We therefore tested in an open-label trial a quercetin-based supplement in patients with clinically proven IC.
MATERIALS AND METHODS: Twenty-two patients (5 men and 17 women; average age 53.1 years) with classically documented IC received one capsule of Cysta-Q complex (equivalent to 500 mg of quercetin) twice a day for 4 weeks. Symptoms were assessed before and after therapy by the IC problem and symptom indices as well as by global assessment of pain (range 0-10).
RESULTS: Two patients did not complete the study. In the remaining 20 patients, improvement was seen in all three parameters tested. After 4 weeks of treatment, the mean (+/- SEM) problem index improved from 11.3 +/- 0.6 to 5.1 +/- 0.7 (p = .000001), the mean symptom index improved from 11.9 +/- 0.9 to 4.5 +/- 0.5 (p = .000001), and the mean global assessment score improved from 8.2 +/- 0.4 to 3.5 +/- 0.4 (p = .000001). None of the patients experienced any negative side effects, and all but one patient had at least some improvement in every outcome measure.
CONCLUSION: Oral therapy with the quercetin supplement Cysta-Q was well tolerated and provided significant symptomatic improvement in patients with IC. Larger, randomized, placebo-controlled trials appear warranted based on these preliminary open-label results.
© SOTO-USA 2025 - All rights are reserved by SOTO-USA to the electronically printed material herein.
This SOT Literature Page and all its contents herein are published by SOTO-USA solely for the purpose of education. All rights reserved by SOTO-USA to accept, reject or modify any submission for publication. The opinions stated in the electronically printed material herein are those of the authors and do not necessarily represent the opinions of SOTO-USA or other individuals associated with SOTO-USA. SOTO-USA does not guarantee or make any representation that the printed material contained herein is valid, reliable or accurate. SOTO-USA does not assume any responsibility for injury arising from any use or misuse of the printed material herein. The printed material contained herein is assumed to be from reliable sources and there is no implication that the printed material herein present the only, or the best methodologies or procedures for the care or treatment of conditions discussed. It is incumbent upon the reader to verify the accuracy of any diagnosis and treatment information contained herein, and to make modifications as new information and/or research arises.
Vist the wisdom, skill, and humor of Dr. DeJarnette the developer of Sacro Occipital Technique.
Major Bertrand DeJarnette, DC, was a renowned inventor, engineer, osteopath, and chiropractor throughout his long and productive career.